The Zetia controversy and New Year's resolutions will spark new emphasis on treating lipids
The Zetia controversy and New Year's resolutions will spark new emphasis on treating lipids...especially when combo therapy is needed.
We know statins are first-line for lowering LDL and cardiac risk.
But they don't always get patients to their lipid goals. And experts differ about what to do when a statin isn't enough.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote